Physician profile
Eric Phelan
NPI 1386192318
$2,431.87
in general payments reported to CMS, 2019-2025
19 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.74 · 2023: $381 · 2024: $586 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.67 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $297.35 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $282.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $257.30 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $170.05 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $122.80 | 2023-2025 | |
| Lilly USA, LLC | $62.05 | 2025 | Zepbound, Jardiance, Mounjaro |
| Daiichi Sankyo INC. | $54.53 | 2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $52.36 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $47.22 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $39.77 | 2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $20.97 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.61 | 2024 | Belbuca |
| Sumitomo Pharma America, INC. | $15.95 | 2025 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.83 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $14.94 | 2025 | Auvelity |
| Amgen INC. | $14.39 | 2025 | Repatha, Otezla |
| Corium, LLC | $13.69 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Phelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.